Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (321-330 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|July 27, 2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyN T Phippen, A A Secord, S Wolf, et al.
Gynecologic Oncology|September 12, 2022
Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping reviewEric Pujade-Lauraine, David S P Tan, Alexandra Leary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyBradley J Monk, Michael W Sill, Joan L Walker, et al.
Virology|June 18, 2010
High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarraysMartha Luevano, Hans-Ulrich Bernard, Hugo A Barrera-Saldaña, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerG Bogani, B J Monk, M A Powell, et al.
Gynecologic Oncology|March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerRodney P Rocconi, Bradley J Monk, Adam Walter, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Gynecologic Oncology|June 12, 2012
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II studyDana M Chase, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|October 27, 2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancerAdam Walter, Rodney P Rocconi, Bradley J Monk, et al.
Gynecologic Oncology|September 3, 2021
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancerKatherine C Fuh, Michael A Bookman, Joyce F Liu, et al.
Pageof 74

Showing results (321-330 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|July 27, 2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyN T Phippen, A A Secord, S Wolf, et al.
Gynecologic Oncology|September 12, 2022
Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping reviewEric Pujade-Lauraine, David S P Tan, Alexandra Leary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyBradley J Monk, Michael W Sill, Joan L Walker, et al.
Virology|June 18, 2010
High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarraysMartha Luevano, Hans-Ulrich Bernard, Hugo A Barrera-Saldaña, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerG Bogani, B J Monk, M A Powell, et al.
Gynecologic Oncology|March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerRodney P Rocconi, Bradley J Monk, Adam Walter, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Gynecologic Oncology|June 12, 2012
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II studyDana M Chase, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|October 27, 2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancerAdam Walter, Rodney P Rocconi, Bradley J Monk, et al.
Gynecologic Oncology|September 3, 2021
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancerKatherine C Fuh, Michael A Bookman, Joyce F Liu, et al.
Pageof 74